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Background: Inhaled hypertonic saline (HS) has been shown to increase mucociliary clearance (MCC) and improve clinical outcomes in adults and
adolescents with cystic fibrosis (CF). However, in younger children with CF, a large study failed to demonstrate clinical benefits. This discrepancy
could reflect pharmacodynamic differences in theMCC response to HS in different populations.We previously demonstrated the absence of a sustained
effect of HS on MCC in healthy adults and in this study sought to characterize the durability of the MCC response to HS in adults with CF.
Methods: At two study sites, MCC was measured in CF adults using gamma scintigraphy during three separate visits: at baseline, 15 min, and 4 h
after a single dose of HS (7% NaCl, 4 mL). Particle clearance rates at these visits were used to assess the durability of the MCC response to HS.
Results: The average 90-minute clearance rate measured 4 h after HS was significantly increased (21.81% ± 12.8) when compared to baseline
(13.77% ± 8.7, p = .048) and showed no apparent slowing relative to the rate measured 15 min after HS. While not all subjects responded to HS,
the acute response strongly predicted the sustained effect in these subjects (r = 0.896, p b .0001).
Conclusions: These results suggest that, in contrast to healthy adults, a single dose of HS has a prolonged effect on MCC in adults with CF, which
lasts at least 4 h. This may explain its clinical efficacy in this population.
© 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Hypertonic saline; Mucociliary clearance; Airway hydration; Pharmacokinetics1. Introduction
Dehydration of airway secretions is believed to be a critical
step in the pathogenesis of cystic fibrosis (CF) lung diseasethor.
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6/j.jcf.2018.01.001[1]. Impaired anion conductance through the cystic fibrosis
transmembrane conductance regulator (CFTR) and accelerated
sodium transport through the epithelial sodium channel (ENaC)
cause dehydration of airway secretions, alter mucus rheological
properties and impair mucus clearance [2–5]. Poor mucus
clearance, in turn, promotes the development of chronic
infection, inflammation, and progressive airways destruction
[6]. Therapies such as hypertonic saline (HS) that increase the
hydration of airway secretions are expected to improvemucociliary
clearance (MCC) and, thereby, yield clinical benefits. Numerous
studies have indeed demonstrated that HS acutely accelerates
MCC in healthy and diseased individuals, including those with CF
[7–10]. A year-long, placebo-controlled clinical trial of HS in CF
patients by Elkins et al. demonstrated improved lung function, a
marked reduction in exacerbation frequency and reduced require-
ment for antibiotic interventions [11]. As a result, approximately
70% of patients over 6 years of age currently use this therapy [12].
The efficacy of HS in older CF patients has also driven
usage in younger populations. One third of patients under six
years of age were prescribed HS in 2015 [12]. This practice has
evolved despite a large, placebo controlled trial by Rosenfeld et
al. that showed no improvement in clinical outcomes after one
year of treatment in young CF children [13]. Interestingly,
Laube et al. also found, on average, no significant improvement
in MCC immediately after HS inhalation in young CF subjects
(7–14 years) who had normal lung function [14]. Together,
these data suggest that the physiologic response to treatment
with HS may vary with the stage of disease and impact its
resulting clinical efficacy.
Unfortunately, our understanding of HS effects on airway
physiology is incomplete. In vitro studies using normal, human
bronchial epithelial cultures suggested that HS has only a transient
effect on airway surface liquid volume [7, 15]. Studies using CF
epithelia yielded mixed results which depended upon the
experimental conditions [7, 16, 17]. Previous in vivo measure-
ments of MCC in adult CF subjects using gamma scintigraphy
demonstrated that HS acutely accelerated clearance [7, 9, 10] and
led to a sustained improvement (N8 h) in MCC after 2 weeks of
repetitive treatment [7]. In contrast, in vivo measurement of MCC
after HS in healthy individuals revealed that a single dose of HS
only transiently increased mucus clearance, and in fact led to a
significant, paradoxical slowing when measured 4 h post-dose
[18]. These studies leave unanswered whether a single dose of HS
may have a prolonged effect on MCC in adults with CF, in
contrast to the data obtained in healthy individuals, or whether
repeated doses are required to achieve a sustained improvement in
MCC. A durableMCC response after a single dose of HS in adults
with CF could explain the sustained effect seen with repetitive HS
treatment, and might also provide a mechanistic framework to
understand the differential clinical effects of HS in other disease
populations, including young children with CF.
2. Methods
2.1. Study design & subjects
We conducted a two-center, randomized, open-label, cross-
over study to measure the durability of the MCC response to a
single dose of HS in individuals with CF at the University of
North Carolina at Chapel Hill (UNC) and at Johns Hopkins
University (JHU). Subjects were eligible for enrollment if they
were ≥18 years of age and had confirmed, mild-to-moderate
CF-related lung disease, defined by forced expiratory volume
in one second (FEV1) N 50% of predicted (ppFEV1). Subjects
were excluded if they were pregnant, had unstable disease as
defined by an absolute decline in ppFEV1 of N15% over theprior six months, demonstrated radiographic findings not
considered part of the usual progression of CF-related lung
disease, or had a change in symptoms or medical regimen in
the preceding two weeks.
All subjects completed three separate MCC studies performed
at baseline, 15 min after a dose of nebulized HS (7%NaCl, 4 mL,
via PARI LC Star® nebulizer with PRONEB® Ultra Compres-
sor), and 4 h after HS. Following enrollment, subjects underwent
baseline MCC study and then were randomized to an order for
which to complete the 15-minute and 4-hour studies. Each study
was performed at least three but not N21 days apart. Prior to
each study visit, subjects withheld HS and dornase alfa for at least
3 days. Long and short-acting bronchodilators were withheld
before each study for 12 and 6 h, respectively. Subjects underwent
spirometry testing following 2 puffs of albuterol from a metered
dose inhaler on each study day prior to administration of HS
(prior toMCCmeasurement on baseline study days), which served
as a verification of the subject's clinical stability as well as pre-
treatment prior to HS administration.
Informed consent was obtained from each subject prior to
enrollment. The study was reviewed and approved by the
institutional review boards at UNC and JHU. The study was
registered on ClinicalTrials.gov (NCT01094704).
2.2. Measurement of MCC rate
During each study visit, subjects inhaled radiolabeled particles
(Tc99m-sulfur colloid) using a standard operating procedure at the
two centers, followed by gamma scintigraphy, with only minor
procedural variations [19]. In procedures performed at UNC, two
fiducial markers containing Am241 (0.9 μCi each) were placed
over the subject's spine at approximately C7 and L1 to facilitate
alignment of the serial images obtained during the MCC scan,
and a Co57 planar source was used to obtain a transmission image
to define lung borders and regions of interest (ROI). At Johns
Hopkins University, a low-dose external source of Tc99m was
briefly held at the sternal notch of the patient before the start of
each imaging procedure to assist with alignment of the subject
with a reference mark on the computer screen. In place of a
transmission scan, a Xe133 gas equilibrium scan, obtained by
rebreathing 1–2 mCi of Xe133 through a Pulmonex system
(Atomic Products, Shirley, NY) until equilibrium was achieved,
was used to identify lung borders and define ROIs.
Radiolabeled sulfur colloid particles suspended in 0.9%
saline were aerosolized with a jet nebulizer (DeVilbiss® Model
646; Mass Median Aerodynamic Diameter: 5 μm). In order to
standardize particle deposition, subjects breathed in time to a
metronome (1 beat/s) to maintain a 1-second inspiratory time,
and used visual feedback to maintain an inspiratory flow rate of
0.5 L/s, as described previously [19]. Approximately 40 μCi
was deposited in the lung over 2–3 min using real time
monitoring. Immediately following isotope inhalation, subjects
gargled and swallowed water to clear retained isotope from the
oropharynx. Gamma emission images from the lungs were
recorded serially over the ensuing 94 min using two-minute
acquisitions. After an initial 64 min of imaging, subjects were
asked to perform a series of 20 coughs every 10 min (60 coughs
total). Subjects returned the following day for a 30-minute
image to assess particle retention after 24 h.
2.3. Image analysis and clearance quantification
Images obtained from both sites were centrally analyzed at
UNC. The Cobalt transmission (UNC) and Xenon gas equilib-
rium (JHU) scans were used to identify and outline the lung
fields, as previously described [18, 19]. Because swallowed
particles in the stomach overlying the lower left lung field
confound analysis of clearance from this lung region, only the
right lung field was analyzed. A whole lung rectangular region of
interest (ROI) was created for the entire right lung field using
either the transmission or gas equilibrium scan from each patient
[20]. The total gamma activity in the ROI was measured,
correcting for isotope decay and background activity, and plotted
as a fraction of the initial activity measured between 0–4 min
post-inhalation. Percent clearance of isotope, defined by 100 ×
(1 − retention), was calculated at 10-minute intervals. The total
percent clearance through 24 h was measured by acquiring a
single 30-minute image at this time point and performing
appropriate decay- and background-corrections. Average isotope
clearance through 90 min (Ave90Clr), which incorporates both
cilia- and cough-driven clearance, was the pre-defined primary
outcome measure. Ave90Clr was calculated by averaging the
nine clearance measurements made at 10-minute intervals. This
single parameter, therefore, utilizes all data points to describe the
entire clearance curve, and is directly proportional to the area
under the clearance curve. Secondary outcome measures
included average isotope clearance through 60 min (Ave60Clr,
representing predominantly cilia-driven clearance), isotope
clearance between 60 to 90 min while voluntary coughs were
being performed (Ave60-90Clr, representing cough and cilia-
driven clearance), and 24-hour clearance.
The heterogeneity of particle deposition was described by the
statistical measure of skew, a unit-less measure of the asymmetry
of a probability distribution. The skew of the deposition
histogram in the whole lung ROI was obtained from the initial
gamma scintigraphic image and was calculated in order to
compare particle deposition at different visits as a potential
covariate that might explain changes in MCC rates. Skew was
used in favor of the more commonly used central to peripheral
ROI (C/P) activity ratio as the primary description of deposition
because the methods used to normalize C/P to lung thickness at
the two centers (Cobalt transmission vs Xenon equilibrium scans)
yields different results and cannot be directly compared [20].
Higher skew values typically indicate foci of greater signal
intensity in large airways, and, like C/P, have been shown to
correlate with accelerated particle clearance [21–23].
2.4. Statistical analyses
The predefined primary analysis was a comparison of whole-
lungAve90Clr at baseline and 4 h post-HS treatment using a two-
tailed Wilcoxon matched-pairs signed rank test to determine
whether HS had a prolonged effect on MCC. Secondary analyses
included similar comparisons of skew, Ave60Clr, Ave60-90Clr,and 24-hour clearance at the different visits (baseline, 15 min,
and 4 h after HS). The correlation (using Spearman's method)
between the acute (Ave90Clr15min − Ave90Clrbaseline) and
sustained (Ave90Clr4h − Ave90Clrbaseline) effect of HS on MCC
within each subject was calculated to investigate this relationship.
The correlation between mucociliary clearance (Ave90Clr)
and particle deposition pattern (skew) at each visit was calculated
in a similar fashion to examine deposition-clearance relation-
ships. Finally, to determine whether any observed changes in
mucociliary clearance could be explained by alterations in
deposition, the correlation between the change in clearance
versus the change in deposition skew was also calculated.
3. Results
3.1. Subjects
Fourteen subjects were recruited from the two centers: four
from JHU and ten from UNC. One subject was excluded from
data analysis as an outlier after being found to have an extreme
difference in isotope deposition at both post-HS studies (skew N 4
standard deviations from the overall mean value), which
precluded meaningful interpretation of this subject's MCC data.
Importantly, inclusion of this subject would have created a bias
that favored our hypothesis and final conclusions, and exclusion
of these data did not change the statistical significance of our data.
Subject characteristics of the remaining 13 subjects are described
in Table 1.
Of note, ten subjects (77%) were being treated with HS at
enrollment, of which seven (54%) were also being treated with
dornase alfa. One subject was being treated with ivacaftor/
lumacaftor at the time of enrollment and was continued
throughout the study.
3.2. Mucociliary clearance and cough clearance
Fig. 1 shows the mean particle clearance curves of inhaled
radiotracer particles through 90 min at each study visit. As
shown, particle clearance 4 h after HS is faster than baseline, with
no indication of slowing relative to the clearance curve obtained
15 min after HS inhalation. In the primary analysis, Ave90Clr
was significantly increased 4 h after HS treatment (21.81% ±
12.8), compared to baseline (13.77% ± 8.7) (p = .048, Fig. 2).
Other MCC parameters, including Ave60Clr and 24-h clearance
were also increased 4 h after HS inhalation, further supporting
the primary outcome (Table 2). Importantly, there were no
differences in the number spontaneous coughs (average
ranging from 6.2 at baseline to 2.9 at the 4-h visit) observed
across the treatment periods that would explain these effects, and
clearance during the cough period was not different from
baseline. Detailed MCC results for individual subjects are
included in Supplementary Table 1.
Although the pattern of MCC acceleration was quantitatively
similar when measured 15 min after baseline, the change from
baseline was not statistically significant. However, most striking
was the very strong correlation between the acute and sustained
effect of HS (post-treatment minus baseline) in individual subjects
Table 1
Subject characteristics.
Subject Age Sex Genotype Baseline FEV1 CFRD Prescribed HS Prescribed dornase Chronic pseudomonas
JHU 1 38 F F508del/3849 + 10 kb C N T 75% No Yes Yes Yes
2 24 M F508del/F508del 70% No Yes Yes Yes
3 18 M F508del/H939R 94% No No No No
UNC 4 36 F F508del/F508del 64% Yes Yes Yes Yes
5 37 F F508del/2789 + 5G N A 85% No No No No
6 22 F F508del/F508del 107% No No No Yes
7 28 M F508del/F508del 70% No Yes No Yes
8 28 F F508del/F508del 79% Yes Yes Yes Yes
9 22 M F508del/F508del a 77% No Yes Yes Yes
10 32 M F508del/F508del 72% No Yes No No
11 38 M F508del/R347P 71% No Yes Yes No
12 30 F F508del/Y913X 72% No Yes Yes Yes
13 55 F 2789 + 5G N A/2789 + 5G N A 74% No Yes No Yes
a Indicates patient being treated with lumacaftor/ivacaftor.(r = 0.896, p b .0001, Fig. 3A and B). This tight correlation
demonstrates the repeatability of the MCC assay and reveals that
the acute response to HS accurately predicted a prolonged
pharmacodynamic benefit. Finally, this suggests that the trend
toward more skewed particle deposition seen only at the 4-hour
post-HS scan did not drive the sustained acceleration of MCC.3.3. Particle deposition
Across all subjects, skew significantly correlated with
Ave90Clr at baseline and 15 min post-HS, but did not reach
significance at 4 h post-HS (r = −0.72 at baseline [p = .007], −
0.63 at 15 min [p = .025], and −0.54 at 4 h [p = .058]). These data
confirm the relationship between initial particle deposition and
MCC rates. Importantly, no significant difference in mean skew
values was observed between the three study visits (Table 2).
Nevertheless, we also explored whether within subject changes in
particle deposition skew could explain faster MCC rates 4 h after
HS inhalation. The absence of a significant correlation between
changes in skew and AveClr90 (r = 0.264, p = .384), suggests
that the observed prolonged improvement in MCC was notFig. 1. Curves demonstrating average isotope clearance across all subjects versus t
represents cilia-driven clearance, whereas cough-assisted clearance is assessed betwattributable to changes in the heterogeneity of particle deposition.
Although skew was used as the primary measure of initial
particle deposition, for reasons described above, C/P values were
calculated and are reported in Supplementary Table 1. A
significant increase in C/P was observed at 4 h compared
to baseline (p = .004), although no difference was observed at
15 min (p = .376).4. Discussion
Our data suggest that, in contrast to healthy individuals [18], a
single dose of HS in adults with CF improves mucus clearance
with an effect that, on average, lasts at least 4 h. Although the
observed acute response to HS did not reach statistical
significance in this small study, and the size of the acute response
to HS is quantitatively consistent with that reported in a prior study
(Ave60Clr in prior study vs current study: Baseline 9.3 ± 1.1% vs
10.5 ± 2.1%, acute HS 17.2 ± 2.9% vs 16.2 ± 3.1%) [7]. Further-
more, the prolonged effect of a single dose of HS we observed
here may explain the N8 h acceleration in MCC that was
previously observed after repeated HS use (Ave60Clr measuredime (±SEM) from the whole lung compartment at each visit. The first 60 min
een 60 and 90 min after isotope inhalation.
Fig. 2. A plot showing individual average 90-minute clearance (Ave90Clr) in
the whole right lung compartment at baseline, 15 min, and 4 h after inhaling
HS. Individual responses are connected with grey lines. In a paired analysis,
Ave90Clr was significantly faster at 4 h compared to baseline (p = .048).8–12 h after HS in prior study: 14.1 ± 1.1%, vs. 18.7 ± 3.2% 4 h
after HS in current study). These data support the hypothesis that
the clinical benefits of HS in individuals with established CF-
related lung disease results from a prolonged effect on mucus
transport, rather than repeated short-duration effects. Interestingly,
the substantial impact of pulmonary exacerbations observed by
Elkins et al. occurred despite adherence to twice daily dosing that
ranged from only 60–72% (Supplementary appendix) [11]. This,
again, supports the concept that fairly infrequent HS dosing is
beneficial because of its durable effect on MCC.
In light of these data, the lack of apparent clinical benefit in
young children with CF raises the question whether the
pharmacodynamic response to HS in this population is more
similar to short duration effect we previously observed in
healthy individuals [18]. This conjecture is supported by
findings from Laube et al. [14], where acute HS effects were
not robust in relatively healthy CF children with normal lung
function, although sustained effects were not assessed. The link
between a prolonged physiologic effect of HS in CF adults and
clinical improvements also suggests that novel hydrator agents
in development should strive to achieve similarly prolonged
effects on MCC. Our data provide a reference comparison for
these investigational therapies, while emphasizing that selection
of the study population, such as age or severity of disease, mayTable 2
Average whole right lung MCC parameters. The average value across al
4 h post-HS treatment, the p-value of a Wilcoxon matched-pairs signed r
Baseline
Average 90 min clearance 13.77% ± 8.7
Average 60 min clearance 10.52% ± 7.6
Average 60–90 min clearance 6.01% ± 7.2
24-hour clearance 26.56% ± 15.4
Skew 2.21 ± 1.22
a Denotes a comparison with a p-value b.05.have profound effects on study outcomes. The need for long-
acting non-osmotic hydrators, including CFTR modulators and
ENaC inhibitors, is supported by the observation that individual
patients and different disease phenotypes may have less robust
responses to an osmotic hydrator such as HS.
The finding that a single dose of HS accelerates clearance in
CF adults for more than 4 h raises questions about the underlying
mechanism. It was previously proposed that the absence of the
CFTR conductive pathway could potentially slow absorption of a
hyperosmotic salt solution, leading to prolonged MCC effects
[7]. However, the absence of clinical benefits in younger CF
populations suggests that the prolonged effect of HS in CF adults
might be attributable to other factors, and not as a direct result of
CFTR dysfunction.
The 2-gel model of the airway surface liquid layer that has
been proposed posits that the overlying, secreted mucus gel
layer may absorb excess fluid [5]. In established CF lung
disease, the volume of secreted airway mucus is often markedly
expanded and significantly dehydrated [24]. This dehydrated
mucus load may, in turn, provide a large capacity to retain
water drawn into the luminal compartment by HS, while
reducing its solids content and improving its transportability. In
the healthy lung, and perhaps the mildly affected CF lung, a
relatively sparse, well-hydrated mucus layer could eliminate the
capacity to store volume driven into the airway lumen by HS,
resulting in its rapid transepithelial reabsorption and a short
duration effect on MCC. In this study, no correlation was found
between sustained HS response and disease severity as
represented by baseline FEV1 (r = −0.325, p = .276) or baseline
Ave90Clr (r = −0.231, p = .448).
Our study data also demonstrates that the response to HS in
CF adults is variable, and likely reflects local differences in the
airway milieu between patients. The fraction of subjects with a
sustained increase in MCC after HS (9/13 with a positive
response to HS; 7/13 with N5% absolute increase in Ave90Clr at
the 4 h time point) is similar to what was observed in our prior
study of HS in CF [7], and is also consistent with the variability in
responses observed by Laube et al. [14]. Unfortunately, our study
was too small to identify clinical features (such as those listed in
Table 1 and referenced in Fig. 3A) that might predict the MCC
response to HS, and we cannot directly link this physiologic
response to clinical benefits. The identification of clinical features
or biomarkers that predict a HS response (such as percent solids
content of sputum or mucin concentration) could potentiallyl subjects is shown, ±the standard deviation. For values 15 min and
ank test is shown for within-subject comparisons to baseline values.
15 min post-HS 4 h post-HS
18.90% ± 12.2 (p = .305) 21.81% ± 12.8 (p = .048) a
16.17% ± 11.3 (p = .244) 18.66% ± 11.5 (p = .017) a
3.60% ± 3.6 (p = .376) 8.65% ± 6.6 (p = .191)
33.26% ± 17.4 (p = .244) 38.19% ± 19.3 (p = .048) a
2.06 ± 1.38 (p = .588) 2.63 ± 1.28 (p = .244)
Fig. 3. A: Waterfall plot of the acute (black bars) and sustained (grey bars) change in clearance after HS in individual subjects, ordered by the acute response. B: Plot
of sustained versus acute clearance showing a significant correlation (r = 0.896, p b .0001) approaching the line of identity (dotted line).assist in the identification of individuals who will benefit from
HS.
One limitation of this study was the use of different methods
used to identify lung borders (Xenon equilibrium at JHU versus
transmission scan at UNC) and normalize lung thickness. As
result of this difference, C/P ratios could not be reliably
compared across subjects. This difference led us to rely on
deposition skew as the primary descriptor of particle deposition.
Importantly, skew was in fact strongly correlated to particle
clearance at baseline, whereas C/P was not (r = 0.72, p b .01; vs.
0.25, p = .40). Suggesting that it is a more reliable index of
deposition with regards to the potential interaction between
particle deposition and clearance. However, for the sake of
completeness, paired comparisons of C/P ratios were made and
revealed a significant difference in C/P between the 4-h and
baseline scans. Although this could have contribute to faster
clearance at the 4-h scan, we note that the quantitatively similar
(but non-significant) increase in clearance 15-minute post-HS
was observed without a change in C/P (p = .38) or skew, and the
intra-subject correlation between acute and sustained HS effects
were highly correlated (Fig. 3). Together with the observation
that 4-h clearance from the peripheral lung region, which is
relatively independent of deposition, was nearly double that atbaseline (8.5% vs 4.8%; p = .203), adds to the evidence that a
true sustained acceleration in MCC occurred. We speculate
that the higher C/P value 4 h after HS may be a result of the
sustained acceleration of MCC rather than driver of it, as mucus
moving from the periphery into the central compartment is
expected to increase central deposition due to impaction from
turbulent flow.
By further delineating the physiologic effects and pharma-
codynamic profiles of HS in different populations, we may be
able to achieve more personalized treatment approaches that
accentuate the benefits of therapies like HS while reducing the
amount of ineffective use and potential side effects. Additional
mechanistic studies in mildly affected CF children and other
potential target populations are needed to reach this goal. In an
era of multiple treatment options and high treatment burden,
this would be of significant interest to patients and the CF
community. The use of an integrated biomarker, such as MCC,
to not only identify effective novel therapeutics, but to also help
us understand the populations that are most likely to benefit has
the potential to move us toward our goal of more personalized
care irrespective of genotype-specific therapies.
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.jcf.2018.01.001.
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